An interventional study of Smartphone-Assisted Single-Session Psychotherapy Intervention in Postpartum Depression, Depression and Postpartum, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment
Our goal is to learn whether a single session of online psychotherapy, followed by four weeks of support from a smartphone app (Motherly), reduces depressive symptoms in women with postpartum depression. Specifically, we want to see if mothers receiving this care show greater improvement-as evaluated by a healthcare professional-than those waiting to start treatment.
We will compare the intervention with a waitlist control. Women in the waitlist group receive the same intervention after 4 weeks.
Participants will:
Background. Postpartum depression (PPD) affects about 17% of women worldwide and carries risks of chronicity, suicidality and impaired child development. Psychotherapy is effective, but access is limited in low- and middle-income countries by workforce shortages and unequal distribution of services. Tele-mental health, smartphone apps and single-session psychotherapy are scalable alternatives. Evidence for single-session psychotherapy in PPD is limited to two trials of multi-hour group workshops, and no trial has combined an individual single session with digital support.
Design. Parallel-group, two-arm randomized controlled trial with masked outcome assessment, conducted remotely in Brazil. A total of 104 women aged 18-40 years, up to 12 months postpartum, with a DSM-5-TR diagnosis of major depressive disorder will be randomized to (1) smartphone app-supported single-session psychotherapy or (2) waitlist control. Assessments occur at T1 (week 1, baseline), T2 (week 2, mid-treatment), T3 (week 4, post-treatment) and T4 (week 8, follow-up). A pilot study to test procedures was completed before the start of recruitment.
Recruitment and screening. Participants are recruited through social media and the project website. Stage 1 is an online eligibility form. Stage 2 is a telephone or video interview to confirm criteria and a diagnostic assessment with the Mini-International Neuropsychiatric Interview (MINI). Eligible women sign an electronic informed consent form before randomization.
Intervention. One online single-session psychotherapy of about 90 minutes, based primarily on behavioral activation (BA). Components: pre-session questionnaire; rapport and assessment of daily routine, reinforcers and support networks; psychoeducation on the behavioral model of depression; collaborative scheduling of achievable, value-aligned activities and problem-solving of barriers and avoidance; training in the Motherly app; session closing and commitment. Optional components (stress management, emotion regulation, cognitive restructuring, sleep hygiene) are used according to clinical judgment. Participants then use the Motherly app independently for 4 weeks. The app includes modules on behavioral activation, emotion regulation, stress management, cognitive restructuring, sleep hygiene and relaxation, and mindfulness, plus activity scheduling, symptom tracking and an educational library. Therapists are psychologists who receive 10 hours of training and are supervised by senior researchers.
Control. Waitlist with no intervention for 4 weeks after randomization, after which participants receive the same intervention. Women with current suicidal ideation with intent or plan, a recent suicide attempt, or treatment-resistant depression are excluded because a waitlist is not appropriate for them.
Randomization and masking. The randomization list is generated by an independent statistician in R and allocation is automated through the REDCap randomization module, ensuring concealment. Outcome assessors are masked and have no role in recruitment, allocation notification, intervention delivery or fidelity assessment. Measures that could reveal allocation are collected online after the clinician-rated assessment. Access to allocation data in REDCap is restricted by role. At post-treatment, assessors guess each participant's allocation and rate their confidence, and masking success is reported with 95% confidence intervals. The main analysis is run with a pre-specified R script on a dataset with masked group labels.
Sample size. A meta-analysis of eight RCTs of single-session interventions for adult depression (Metapsy database, version 24.0.2) gave g = 0.60. With two-sided alpha of 5%, 80% power and 15% attrition, 104 participants are required (G*Power 3.1.9.4).
Statistical analysis. Primary and secondary outcomes will be analyzed with generalized estimating equations (GEE) with an AR(1) working correlation structure and robust sandwich variance estimator, in the intention-to-treat sample. Each model includes the outcome as dependent variable and group, time (categorical) and the group-by-time interaction as predictors. Marginal means will be compared with pairwise comparisons. Missing data will be handled with multiple imputation by chained equations under a missing-at-random assumption. Standardized effect sizes (Cohen's d) will be computed from marginal means and observed standard deviations. Sensitivity analyses will compare results with completers only, and baseline predictors of dropout will be examined. Significance level is p \< 0.05 with 95% confidence intervals.
Moderators (exploratory). Interaction models will test maternal age, skin color/ethnicity, education, family income, number of previous children, relationship with the father, perceived social support (MSPSS), baby's age, time spent with the child, number of pediatric and prenatal consultations, baseline depression (QIDS-SR16, QIDS-C16), baseline severity (CGI-S) and functioning (SDS). The trial is not powered for these analyses.
Mediators (exploratory). Behavioral activation and avoidance (modified BADS-SF, two-week recall) and environmental reward (Reward Probability Index) are assessed at T1 and T2. Parallel mediation models will test whether they mediate the effect on depressive symptoms at T3, adjusting for baseline levels of symptoms and mediators. Depressive symptoms at T2 will also be considered to account for early change.
Treatment-specific processes (intervention arm). Therapeutic alliance (WAI-SR, client and therapist versions, at T2) and seven app engagement indicators will be related to clinical outcomes with regression models.
Fidelity. An independent rater will assess adherence from audio recordings of the sessions, using a checklist adapted from a previous behavioral activation study.
Safety. Adverse events are recorded at post-treatment and follow-up. Clinical worsening is defined as an increase of 30% or more in the QIDS-16 total score (clinician-rated or self-report) relative to baseline. Serious adverse events include death, life-threatening events, hospitalization, significant disability and suicide risk (score of 2 or more on QIDS-16 item 12). REDCap sends automatic alerts to the investigators. Participants with emerging suicidal ideation receive a written safety plan and are referred for psychiatric evaluation; domestic violence is addressed with referrals to specialized services. Participants without remission at the end of the study are referred to specialized care.
Ethics. Approved by CAPPesq, HC-FMUSP (CAAE 97532226.8.0000.0068; approval 8.574.338). Conducted in accordance with the Declaration of Helsinki.
Registration note. The protocol was submitted to the Brazilian Clinical Trials Registry (ReBEC; UTN U1111-1345-9666) on [PREENCHER data], before the start of recruitment, but was not published by that registry. This ClinicalTrials.gov record was created after the first participants were enrolled. No changes to outcomes or analyses were made.
569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.
This study's planned enrollment of 104 is close to the median of 104 across 454 interventional studies indexed under Depression, Postpartum.
Browse Depression, Postpartum studies →University of Sao Paulo is the lead sponsor of 1,035 studies on the registry; 95 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Smartphone-Assisted Single-Session Psychotherapy Intervention: one online psychotherapy session of about 90 minutes based primarily on behavioral activation, delivered by a trained psychologist, followed by 4 weeks of self-guided use of the Motherly app.
Behavioral: Smartphone-Assisted Single-Session Psychotherapy Intervention
Waitlist control: no intervention for 4 weeks after randomization. Participants then receive the same app-supported single-session psychotherapy.
A single online psychotherapy session (about 90 minutes) based primarily on behavioral activation: psychoeducation on the behavioral model of depression, identification of reinforcers and avoidance, collaborative scheduling of achievable value-aligned activities, problem-solving of barriers, and training in the Motherly app. Optional components (stress management, emotion regulation, cognitive restructuring, sleep hygiene) are used according to clinical judgment. A pre-session questionnaire tailors the session. Participants then use the Motherly app for 4 weeks to schedule and track activities, monitor symptoms and access modules on behavioral activation, emotion regulation, stress management, cognitive restructuring, sleep hygiene and mindfulness. The intervention is delivered by psychologists with 10 hours of training and senior supervision.
Depressive symptoms (clinician-rated)
Total score on the Quick Inventory of Depressive Symptomatology, Clinician-Rated (QIDS-C16), administered by masked assessors. Range 0-27; higher scores indicate more severe depression.
Time frame: Week 4 (post-treatment, T3)
Depressive symptoms (self-report)
Total score on the Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16). Range 0-27; higher scores indicate more severe depression.
Time frame: Week 4 (T3) and week 8 (T4)
Anxiety Symptoms
Total score on the Generalized Anxiety Disorder 7-item scale (GAD-7). Range 0-21; higher scores indicate more severe anxiety.
Time frame: Week 4 (T3) and week 8 (T4)
Sleep problems
Global score on the Pittsburgh Sleep Quality Index (PSQI). Range 0-21; higher scores indicate worse sleep quality.
Time frame: Week 4 (T3) and week 8 (T4)
Parental distress
Parental Distress subscale of the Parenting Stress Index Short Form (PSI-SF). Range 12-60; higher scores indicate more stress.
Time frame: Week 4 (T3) and week 8 (T4)
Parent-child dysfunctional interaction
Parent-Child Dysfunctional Interaction subscale of the PSI-SF. Range 12-60; higher scores indicate more stress.
Time frame: Week 4 (T3) and week 8 (T4)
Parenting stress
Total score of the PSI-SF. Range 36-180; higher scores indicate more stress.
Time frame: Week 4 (T3) and week 8 (T4)
Functional impairment
Total score on the Sheehan Disability Scale (SDS), covering work/school, social life and family life. Range 0-30; higher scores indicate more impairment.
Time frame: Week 4 (T3) and week 8 (T4)
Change in depression severity and functional impairment relative to baseline
Clinical Global Impression - Improvement (CGI-I), rated by masked assessors relative to baseline (T1). Range 1 (very much improved) to 7 (very much worse).
Time frame: Week 4 (T3)
Postnatal depressive symptoms (EPDS)
Total score on the Edinburgh Postnatal Depression Scale. Range 0-30; higher scores indicate more symptoms. Used for comparison with the PPD literature.
Time frame: Week 4 (T3), week 8 (T4)
Plan to share: Yes — De-identified individual participant data underlying the published results will be shared upon reasonable request to the principal investigator.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: After publication of the main findings.
Access criteria: Reasonable request to the principal investigator (daniel.fatori@usp.br), subject to approval by the investigators.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.
Of 256 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 8 months is below that.
Counting every sponsor, half of 262 studies reached it within 23 months; a quarter within 11 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.